Picamilon

File:Picamilon2d.png

2D structure of Picamilon

File:Picamilon3d.png

3D structure of Picamilon

File:Picamilon.jpg

Picamilon

Picamilon (also known as nicotinoyl-GABA, Pikamilon, or Pikatropin) is a dietary supplement formed by combining niacin with GABA. It was developed in the Soviet Union in 1969 by the All-Union Vitamins Scientific Research Institute and further studied in both Russia and Japan as a prodrug of GABA.

History

Picamilon was first synthesized in the Soviet Union in 1969 at the All-Union Vitamins Scientific Research Institute. It was developed as a prodrug of GABA (gamma-aminobutyric acid), a naturally occurring inhibitory neurotransmitter in the brain. The addition of a niacin molecule increases the ability of GABA to cross the blood-brain barrier and reach the brain.

Pharmacology

Picamilon is a prodrug of GABA, meaning it is metabolized into GABA in the body. It is believed to have nootropic effects, which means it may improve cognitive function. However, the exact mechanisms of action are not fully understood. It is also thought to have vasodilatory effects, which means it may widen blood vessels and improve blood flow.

Uses

Picamilon has been used in Russia as a prescription drug to treat a variety of conditions, including depression, anxiety, and cerebrovascular disorders. It is also used as a dietary supplement in the United States, although it is not approved by the Food and Drug Administration (FDA) for any specific medical use.

Safety and legality

In 2015, the FDA determined that Picamilon does not meet the definition of a dietary ingredient and issued warning letters to companies selling products containing Picamilon. As a result, many companies have stopped selling Picamilon supplements in the United States.

See also

• Phenibut
• Nootropic
• GABA
• Niacin